Immune Profile And Outcomes Of Patients (Pts) With Gynecological Malignancies (Gyn) Enrolled In Early Phases Immunotherapy (Io) Trials.

5595Background: Immune checkpoint inhibitors have shown promising activity in multiple tumor types. However, there are no approved IO for GYN. Methods: We identified GYN pts treated with IO from 2014-2017 in phase I/II trials at Vall d´Hebron. Tumor infiltrating lymphocites (TILs); PD-L1 expression by immunohistochemistry (IHC) (SP263 antibody); microsatellite instability (MSI) by IHC and Gynecological Immune Prognostic Index (GIPI) (baseline derived NLR (dNLR) (neutrophils/(leucocytes-neutrophils)) u003e 3 and LDH u003e upper limit of normal) were correlated with outcomes. Results: Sixty GYN cases (32 ovarian (OC); 8 endometrial(EC);15 cervical(CC) and 5 vulvar (VC)) were selected. Median number of metastatic sites and prior lines were 2 (1-4) and 2 (0-8) respectively. Median TILs was 10% (1%-90%); 10% of pts had high TILs (≥ 50%) and CC showed higher TILs (p = 0.007). PD-L1 u003e 1% was shown in 60% of pts (46% OC, 43% CC, and 11% EC). Single agent IO involved 47% of cases. Median follow-up was 69m. Overall respons...